Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study

P Borchmann; T van Meerten; P Bories; P Dreger; L Gopsca; P Mutsaers; M Edinger; A Illes; B von Tresckow; Peter Neumeister; N Steiner; U Jaeger; AT Moreno; L Griskevicius; G Iacoboni; F Lemonnier; J van Doesum; N Shah; R Orentas; S Miltenyi; T Overstijns; I Bürger; G Zadoyan; C Brillant; P van Heteren; S Holtkamp; P Vandenberghe

doi:10.1182/blood-2025-669

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study

P Borchmann
, T van Meerten
, P Bories
, P Dreger
, L Gopsca
, P Mutsaers
, M Edinger
, A Illes
, B von Tresckow
, Peter Neumeister
, N Steiner
, U Jaeger
, AT Moreno
, L Griskevicius
, G Iacoboni
, F Lemonnier
, J van Doesum
, N Shah
, R Orentas
, S Miltenyi

T Overstijns, I Bürger, G Zadoyan, C Brillant, P van Heteren, S Holtkamp, P Vandenberghe

Division of Haematology

Research output: Contribution to journal › Conference abstract

Original language	English
Journal	Blood
DOIs	https://doi.org/10.1182/blood-2025-669
Publication status	Published - 2025
Event	67th Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando, United States Duration: 6 Dec 2025 → 9 Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

DOI

10.1182/blood-2025-669

Links

Web of Science

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study
Borchmann, P. (Author), van Meerten, T. (Author), Bories, P. (Author), Dreger, P. (Author), Gopsca, L. (Author), Mutsaers, P. (Author), Edinger, M. (Author), Illes, A. (Author), von Tresckow, B. (Author), Neumeister, P. (Author), Steiner, N. (Author), Jaeger, U. (Author), Moreno, A. (Author), Griskevicius, L. (Author), Iacoboni, G. (Author), Lemonnier, F. (Author), van Doesum, J. (Author), Shah, N. (Author), Orentas, R. (Author), Miltenyi, S. (Author), Overstijns, T. (Author), Bürger, I. (Author), Zadoyan, G. (Author), Brillant, C. (Author), van Heteren, P. (Author), Holtkamp, S. (Author) & Vandenberghe, P. (Author)
2025
Activity: Talk, presentation or poster › Poster

Cite this

Borchmann, P., van Meerten, T., Bories, P., Dreger, P., Gopsca, L., Mutsaers, P., Edinger, M., Illes, A., von Tresckow, B., Neumeister, P., Steiner, N., Jaeger, U., Moreno, AT., Griskevicius, L., Iacoboni, G., Lemonnier, F., van Doesum, J., Shah, N., Orentas, R., ... Vandenberghe, P. (2025). Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study. Blood. https://doi.org/10.1182/blood-2025-669

@article{4955cd5fc44140f0ad0ad7bcf734650c,

title = "Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study",

author = "P Borchmann and \{van Meerten\}, T and P Bories and P Dreger and L Gopsca and P Mutsaers and M Edinger and A Illes and \{von Tresckow\}, B and Peter Neumeister and N Steiner and U Jaeger and AT Moreno and L Griskevicius and G Iacoboni and F Lemonnier and \{van Doesum\}, J and N Shah and R Orentas and S Miltenyi and T Overstijns and I B{\"u}rger and G Zadoyan and C Brillant and \{van Heteren\}, P and S Holtkamp and P Vandenberghe",

year = "2025",

doi = "10.1182/blood-2025-669",

language = "English",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

note = "67th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 06-12-2025 Through 09-12-2025",

}

Borchmann, P, van Meerten, T, Bories, P, Dreger, P, Gopsca, L, Mutsaers, P, Edinger, M, Illes, A, von Tresckow, B, Neumeister, P, Steiner, N, Jaeger, U, Moreno, AT, Griskevicius, L, Iacoboni, G, Lemonnier, F, van Doesum, J, Shah, N, Orentas, R, Miltenyi, S, Overstijns, T, Bürger, I, Zadoyan, G, Brillant, C, van Heteren, P, Holtkamp, S & Vandenberghe, P 2025, 'Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study', Blood. https://doi.org/10.1182/blood-2025-669

TY - JOUR

T1 - Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study

AU - Borchmann, P

AU - van Meerten, T

AU - Bories, P

AU - Dreger, P

AU - Gopsca, L

AU - Mutsaers, P

AU - Edinger, M

AU - Illes, A

AU - von Tresckow, B

AU - Neumeister, Peter

AU - Steiner, N

AU - Jaeger, U

AU - Moreno, AT

AU - Griskevicius, L

AU - Iacoboni, G

AU - Lemonnier, F

AU - van Doesum, J

AU - Shah, N

AU - Orentas, R

AU - Miltenyi, S

AU - Overstijns, T

AU - Bürger, I

AU - Zadoyan, G

AU - Brillant, C

AU - van Heteren, P

AU - Holtkamp, S

AU - Vandenberghe, P

PY - 2025

Y1 - 2025

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:1659056200020

U2 - 10.1182/blood-2025-669

DO - 10.1182/blood-2025-669

M3 - Conference abstract

SN - 0006-4971

JO - Blood

JF - Blood

T2 - 67th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 6 December 2025 through 9 December 2025

ER -

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study

UN SDGs

DOI

Links

Activities

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study

Cite this